• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

远程医疗治疗阿片类药物使用障碍:保留率与人口统计学和农村性的关系。

Telehealth for opioid use disorder: retention as a function of demographics and rurality.

机构信息

Department of Psychiatry, Columbia University Medical Center, New York, NY.

Ophelia Health Inc., New York, NY.

出版信息

Am J Drug Alcohol Abuse. 2023 Mar 4;49(2):260-265. doi: 10.1080/00952990.2023.2180382. Epub 2023 Mar 24.

DOI:10.1080/00952990.2023.2180382
PMID:36961998
Abstract

Despite lifesaving medications such as buprenorphine and methadone, the majority of individuals with opioid use disorder (OUD) face access barriers to evidence-based treatment. COVID-19 era regulatory reforms have shown that telehealth can improve access to care, although disparities in clinical outcomes are likely to persist. We aimed to analyze 180-day and 365-day retention in treatment with buprenorphine for OUD overall and by demographics, hypothesizing that retention would be lower among racial/ethnic minorities and rural patients. We analyzed data from a cohort of individuals with OUD enrolled in treatment from April 1, 2020 to September 30, 2021, in Pennsylvania and New York using a virtual-first telehealth OUD treatment platform to assess rates of 180-day and 365-day retention. Associations between demographic characteristics and retention were assessed using unadjusted and adjusted logistic regression models. Among 1,378 patients (58.8% male), 180-day retention was 56.4%, and 365-day retention was 48.3%. Adjusted analyses found that only an association between older age and greater odds of 180-day retention was significant (aOR for patients aged 30-50 vs. <30: 1.83 [1.37-2.45]). There were no significant associations between sex, race/ethnicity, state, or rurality with retention. While we were unable to control for socioeconomic variables, we found retention within telehealth services for buprenorphine was high irrespective of geography or race/ethnicity, but disparities with age indicate a subset of patients who may benefit from more intensive services early in care.

摘要

尽管有丁丙诺啡和美沙酮等救命药物,但大多数阿片类药物使用障碍(OUD)患者在获得基于证据的治疗方面面临障碍。COVID-19 时代的监管改革表明,远程医疗可以改善获得护理的机会,尽管临床结果的差异可能仍然存在。我们旨在分析总体和按人口统计学因素(假设保留率在种族/少数民族和农村患者中较低)使用丁丙诺啡治疗 OUD 的 180 天和 365 天保留率。我们使用虚拟优先远程医疗 OUD 治疗平台分析了 2020 年 4 月 1 日至 2021 年 9 月 30 日期间在宾夕法尼亚州和纽约州接受治疗的 OUD 患者队列的数据,以评估 180 天和 365 天保留率。使用未调整和调整后的逻辑回归模型评估人口统计学特征与保留之间的关联。在 1378 名患者(58.8%为男性)中,180 天保留率为 56.4%,365 天保留率为 48.3%。调整后的分析发现,仅年龄较大与 180 天保留的几率较高之间存在关联(年龄在 30-50 岁与<30 岁的患者相比:1.83 [1.37-2.45])。性别、种族/族裔、州或农村地区与保留率之间没有显著关联。虽然我们无法控制社会经济变量,但我们发现远程医疗服务中丁丙诺啡的保留率很高,无论地理位置或种族/族裔如何,但与年龄相关的差异表明,在护理早期,有一部分患者可能受益于更密集的服务。

相似文献

1
Telehealth for opioid use disorder: retention as a function of demographics and rurality.远程医疗治疗阿片类药物使用障碍:保留率与人口统计学和农村性的关系。
Am J Drug Alcohol Abuse. 2023 Mar 4;49(2):260-265. doi: 10.1080/00952990.2023.2180382. Epub 2023 Mar 24.
2
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.医疗保险受益人的远程医疗服务的接受情况、阿片类药物使用障碍药物的获得和保留情况,以及在 COVID-19 大流行之前和期间的药物治疗过量情况。
JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284.
3
Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.远程医疗在医疗补助受种者阿片类药物使用障碍治疗中的丁丙诺啡起始和维持。
JAMA Netw Open. 2023 Oct 2;6(10):e2336914. doi: 10.1001/jamanetworkopen.2023.36914.
4
Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.在 COVID-19 大流行期间,视频、电话和面对面使用丁丙诺啡治疗阿片类药物使用障碍的情况和保留率。
JAMA Netw Open. 2022 Oct 3;5(10):e2236298. doi: 10.1001/jamanetworkopen.2022.36298.
5
COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.COVID-19:改变阿片类药物使用障碍管理中远程医疗服务提供的催化剂。
Subst Abus. 2021;42(2):205-212. doi: 10.1080/08897077.2021.1890676. Epub 2021 Mar 8.
6
Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.远程医疗启动丁丙诺啡治疗阿片类药物使用障碍:患者特征和结局。
J Gen Intern Med. 2024 Jan;39(1):95-102. doi: 10.1007/s11606-023-08383-1. Epub 2023 Sep 5.
7
Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.移动远程医疗在农村地区阿片类药物使用障碍患者丁丙诺啡治疗中的应用
JAMA Netw Open. 2021 Aug 2;4(8):e2118487. doi: 10.1001/jamanetworkopen.2021.18487.
8
Long-term retention in Office Based Opioid Treatment with buprenorphine.丁丙诺啡在门诊阿片类药物治疗中的长期维持治疗
J Subst Abuse Treat. 2017 Mar;74:65-70. doi: 10.1016/j.jsat.2016.12.010. Epub 2016 Dec 30.
9
The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.新型冠状病毒肺炎疫情和阿片类药物使用障碍:扩大丁丙诺啡治疗,并将安全防范措施与远程医疗相结合。
J Subst Abuse Treat. 2022 Feb;133:108543. doi: 10.1016/j.jsat.2021.108543. Epub 2021 Jun 26.
10
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?新冠疫情时代阿片类物质使用障碍的药物治疗:新规定能否改变阿片类药物使用的恶性循环?
J Subst Abuse Treat. 2021 Mar;122:108196. doi: 10.1016/j.jsat.2020.108196. Epub 2020 Nov 14.

引用本文的文献

1
What waiver? A qualitative exploration of awareness of the X-waiver among underserved patients and providers and the impact on tele-OUD services uptake.什么豁免?对服务不足的患者和提供者对X豁免的认知以及对远程阿片类药物使用障碍治疗服务采用情况的影响进行定性探索。
Front Psychiatry. 2025 Jul 16;16:1589546. doi: 10.3389/fpsyt.2025.1589546. eCollection 2025.
2
Association between different modalities of opioid use disorder-related care delivery and opioid use disorder-related patient outcomes: A retrospective cohort study.阿片类物质使用障碍相关护理提供的不同模式与阿片类物质使用障碍相关患者结局之间的关联:一项回顾性队列研究。
Addict Behav Rep. 2025 Feb 2;21:100588. doi: 10.1016/j.abrep.2025.100588. eCollection 2025 Jun.
3
Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.
阿片类物质使用障碍药物辅助治疗结果中的性别差异:全国代表性门诊诊所数据。
Drug Alcohol Depend. 2025 Feb 1;267:112535. doi: 10.1016/j.drugalcdep.2024.112535. Epub 2025 Jan 3.
4
Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.患者和提供者通过远程医疗接受阿片类物质使用障碍护理的体验:一项系统的混合研究综述。
Drug Alcohol Depend. 2025 Jan 1;266:112522. doi: 10.1016/j.drugalcdep.2024.112522. Epub 2024 Dec 4.
5
Policies, adaptations, and ongoing challenges to naloxone, buprenorphine and nonprescription syringe access across four-states: Findings from an environmental scan and key informant interviews.四个州纳洛酮、丁丙诺啡和非处方注射器获取方面的政策、调整及持续挑战:环境扫描和关键信息提供者访谈的结果
Drug Alcohol Depend Rep. 2024 May 28;11:100243. doi: 10.1016/j.dadr.2024.100243. eCollection 2024 Jun.
6
Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment.使用网络内保险福利对于提高基于远程医疗的丁丙诺啡治疗的留存率至关重要。
Health Aff Sch. 2024 Jan 30;2(3):qxae009. doi: 10.1093/haschl/qxae009. eCollection 2024 Mar.
7
The Opioid Epidemic: A Review of the Contributing Factors, Negative Consequences, and Best Practices.阿片类药物流行:促成因素、负面后果及最佳实践综述
Cureus. 2023 Jul 10;15(7):e41621. doi: 10.7759/cureus.41621. eCollection 2023 Jul.